

**The Japanese Society  
for Child and Adolescent Psychiatry**

c/o Dogura & Co., Ltd  
1-8, Nishihanaikecho, Koyama,  
Kitaku, Kyoto 603-8148, Japan  
Phone: +81-75-451-4844 FAX: +81-75-441-0436  
e-mail: jde07707@nifty.com



一般社団法人  
**日本児童青年精神医学会**

〒603-8148  
京都市北区小山西花池町1-8  
(株) 土倉事務所内  
TEL: 075-451-4844 FAX: 075-441-0436  
e-mail: jde07707@nifty.com

Dear Members of the WHO Expert Committee on Selection and Use of Essential Medicines,

On behalf of the Japanese Society of Child and Adolescent Psychiatry, we would like to express our full support for the application of methylphenidate in the WHO Essential Medicines List: the application ref is “A.19 Methylphenidate – attention deficit hyperactivity disorder”.

We believe that the proposals outlined in the application are well-considered and align closely with the goals of the World Health Organization in promoting better health and well-being.

As a professional committee within the JSCAP, we strongly encourage the committee to give favorable consideration to this application.

Thank you for your attention.

Sincerely,

Noa TSUJII

Toyosaku Ota

On behalf of Committee on Pharmaceutical Affaires of the Japanese Society of Child and Adolescent Psychiatry

17 April 2025

Noa TSUJII, Department of Child Mental Health and Development, Toyama University Hospital

E-mail: [tujiinoa@med.u-toyama.ac.jp](mailto:tujiinoa@med.u-toyama.ac.jp)

2630 Sugitani, Toyama, Toyama, Japan

Toyosaku Ota, Department of Human Development, Faculty of Nursing, School of Medicine, Nara Medical University

E-mail: [toyosaku@naramed-u.ac.jp](mailto:toyosaku@naramed-u.ac.jp)

840 Shijo-Cho, Kashihara, Nara, Japan